Core Viewpoint - Beijing Zhanghong Private Fund Management Co., Ltd. plans to reduce its holdings in Aipeng Medical (300753.SZ) by up to 1% of the total share capital through both centralized bidding and block trading within three months after the announcement [1] Group 1 - The shareholder, Zhanghong Selected No. 1 Private Securities Investment Fund, intends to sell no more than 1,260,500 shares, which represents 1% of the company's total share capital [1] - The planned reduction will occur in two phases: through centralized bidding and block trading, each not exceeding 1% of the total share capital [1]

Core Viewpoint - Aipeng Medical (300753) announced that its shareholder, Beijing Zhanghong Private Fund Management Co., Ltd., plans to reduce its stake by up to 2% through centralized bidding or block trading [1] Group 1 - The shareholder holds a 5.6% stake in Aipeng Medical [1] - The reduction in stake will be executed through either centralized bidding or block trading methods [1]

Core Viewpoint - Beijing Zhanghong Private Fund Management Co., Ltd. plans to reduce its stake in Aipeng Medical by up to 1,260,480 shares, representing 1% of the total share capital, due to personal funding needs [1] Group 1 - The shareholder holds 7,058,000 shares, accounting for 5.60% of the company's total share capital [1] - The planned reduction will occur within three months starting from fifteen trading days after the announcement date, specifically from December 4, 2025, to March 3, 2026 [1] - The reduction will be executed through centralized bidding and block trading methods, with the selling price determined by market conditions [1] Group 2 - The shares being reduced were acquired through an agreement transfer in 2024 [1] - The shareholder is not classified as a controlling shareholder or actual controller of the company, ensuring that the reduction will not lead to a change in control or affect the company's governance structure and ongoing operations [1]

Core Viewpoint - Beijing Zhanghong Private Fund Management Co., Ltd. plans to reduce its stake in Aipeng Medical by selling up to 252.1 thousand shares, which represents 2% of its holdings, due to its own funding needs [1] Group 1: Shareholding Details - Beijing Zhanghong Private Fund Management Co., Ltd. currently holds 7.058 million shares of Aipeng Medical, accounting for 5.60% of the total shares [1] - The shares to be sold consist of 126.05 thousand shares through centralized bidding and another 126.05 thousand shares through block trading, both representing 1% of the total shares [1] Group 2: Timeline and Pricing - The reduction period is set from December 4, 2025, to March 3, 2026 [1] - The selling price will be determined based on market prices during the reduction period [1]

江苏爱朋医疗科技股份有限公司 关于持股5%以上股东减持股份的预披露公告 公司持股5%以上的股东北京章泓私募基金管理有限公司-章泓精选1号私募 证券投资基金保证向公司提供的信息内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示：持有本公司7,058,000股（占公司总股本的5.60%）的持股5%以上股东 北京章泓私募基金管理有限公司-章泓精选1号私募证券投资基金（以下简称"章泓精 选1号"）计划自本公告发布之日起十五个交易日后的三个月内以集中竞价交易方式减 持所持有的本公司股份不超过1,260,480股（占公司总股本的1%）；计划自本公告发布 之日起十五个交易日后的三个月内以大宗交易方式减持所持有的本公司股份不超过 1,260,480股（占公司总股本的1%）。 证券代码：300753 证券简称：爱朋医疗 公告编号：2025-052 | | | 在减持计划实施期间，公司若发生派发红利、送红股、转增股本、增发新股或配 股等除权、除息事项，减持股份数量、股权比例将进行相应调整。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于 ...

Core Insights - The medical device sector experienced a rise of 0.57% on November 12, with Tianyi Medical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Device Sector Performance - Tianyi Medical (301097) closed at 65.30, up 11.34% with a trading volume of 46,500 and a transaction value of 294 million [1] - Jimin Health (603222) closed at 11.33, up 10.00% with a trading volume of 729,500 and a transaction value of 797 million [1] - Zhongyuan Xiehe (600645) closed at 28.61, up 10.00% with a trading volume of 311,400 and a transaction value of 857 million [1] - Other notable gainers include Danah Biotechnology (920009) up 9.99%, Lideman (300289) up 9.89%, and Yipeng Medical (300753) up 8.21% [1] Capital Flow Analysis - The medical device sector saw a net inflow of 739 million from institutional investors, while retail investors experienced a net outflow of 923 million [2][3] - Jimin Health had a net inflow of 205 million from institutional investors, but a net outflow of 138 million from retail investors [3] - Zhongyuan Xiehe also saw a net inflow of 194 million from institutional investors, with a significant net outflow of 932 million from retail investors [3]

Group 1 - The blood oxygen meter concept index rose by 1.56%, ranking fourth among concept sectors, with 14 stocks increasing in value [1] - Key performers included Kexiang Co., which hit the daily limit with a 20% increase, and Aipeng Medical and Huashengchang, which rose by 8.21% and 1.79% respectively [1] - The sector experienced a net inflow of 0.81 billion yuan from main funds, with Kexiang Co. leading the inflow at 2.28 billion yuan [1][2] Group 2 - The top stocks by net inflow ratio included Kexiang Co. at 11.60%, *ST Yitong at 8.95%, and Jinghua Micro at 7.72% [2] - The trading volume for Kexiang Co. was 22.8 billion yuan, with a turnover rate of 29.96% [2] - Other notable stocks included Aipeng Medical with a net inflow of 487.14 million yuan and a turnover rate of 23.39% [2] Group 3 - The blood oxygen meter sector's performance was contrasted with other sectors, such as cell immunotherapy, which rose by 2.20%, and cultivated diamonds, which fell by 4.21% [1] - Stocks with significant declines included Fenda Technology, Sichuan Changhong, and *ST Yitong, with decreases of 1.34%, 0.80%, and 0.54% respectively [1][3] - The overall market sentiment reflected a mixed performance across various sectors, highlighting the volatility within the healthcare and technology industries [3]

Group 1 - The outbreak of respiratory syncytial virus (RSV) in Tianjin has peaked earlier than expected, with flu activity rising in southern provinces and most northern provinces during the 44th week of 2025 [1] - The latest flu monitoring report from the National Disease Control indicates an increase in flu cases, highlighting the need for vigilance against RSV alongside influenza [4] Group 2 - In the A-share market, flu-related stocks are experiencing significant activity, with Aipeng Medical rising over 10%, and other companies like Panlong Pharmaceutical hitting the daily limit, indicating strong investor interest [2] - The detection rates for severe acute respiratory infections show that rhinovirus (10.6%), RSV (8.5%), and influenza virus (4.2%) are the top three pathogens, emphasizing the impact of RSV on public health [4]

Core Viewpoint - The A-share market is seeing active trading in flu-related stocks, driven by an early peak in respiratory syncytial virus (RSV) and flu activity in China, as reported by the National Disease Control [1][2]. Group 1: Market Activity - Aipeng Medical has risen over 10%, while Panlong Pharmaceutical has reached a 10% limit up, with other companies like Rejing Bio and Dongfang Bio also seeing significant gains [1]. - The latest flu monitoring report indicates an increase in flu activity in southern provinces and a rise in northern provinces during the 44th week of 2025 [1]. Group 2: Key Data on Stocks - Aipeng Medical (300753) has a market cap of 3.969 billion and a year-to-date increase of 79.09% [2]. - Panlong Pharmaceutical (002864) has a market cap of 3.788 billion and a year-to-date increase of 18.84% [2]. - Rejing Bio (688068) has a market cap of 14 billion and a year-to-date increase of 144.44% [2]. - Dongfang Bio (688298) has a market cap of 5.836 billion with a slight year-to-date decrease of 1.30% [2]. - Other notable stocks include Te Yi Pharmaceutical (002728) with a market cap of 6.961 billion and a year-to-date increase of 52.45% [2].

Group 1 - The core point of the news is that Shanghai Ladder Medical Technology Co., Ltd. has developed an "implantable wireless brain-machine interface system" which has entered the special review process for innovative medical devices by the National Medical Products Administration (NMPA) in China, marking a significant step in the commercialization of this cutting-edge technology in the country [1] - This product is the first invasive brain-machine interface to enter the "green channel" for medical devices in China, indicating a transition from clinical validation to market access [1] Group 2 - Following this news, A-share market stocks related to brain-machine interfaces have shown strong performance, with Aipeng Medical rising nearly 12%, Century Huatong and Innovation Medical increasing over 7%, and Botuo Bio up over 5% [2] - Other companies in the sector, such as Xiangyu Medical, Sanbo Neuroscience, Saili Medical, Dinake, Taihe Technology, and Chengyitong, have also seen their stock prices rise by over 3% [2]